Literature DB >> 29197837

Bilateral ocular surface squamous neoplasia with bilateral periocular basal cell carcinoma in a case of xeroderma pigmentosum.

Rohit Agarwal1, Bhavna Chawla1, Mohamed Ibrahime Asif1, Amar Pujari1.   

Abstract

Xeroderma pigmentosum (XP) is an autosomal recessive disorder associated with multiple oculocutaneous manifestations.We discuss a unique case of XP having bilateral ocular surface squamous neoplasia (OSSN) and periocular basal cell carcinoma. In the right eye, a large OSSN mass involving the ocular surface extensively along with intraocular invasion was noted, whereas in the left eye, the tumour mass was involving the limbus, and extending up to three clock hours. Because of extensive disease in the right eye, orbital exenteration was performed, and for the left eye, a wide excision of the mass with triple freeze thaw cryo application to the margins followed by amniotic membrane grafting was done. Basal cell carcinoma was noted around the medial canthus on both sides. The right-sided basal cell carcinoma was treated by wide excision followed by a forehead rotation flap and the left-sided lesion was managed with topical 5% imiquimod cream. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  oncology; ophthalmology

Mesh:

Year:  2017        PMID: 29197837      PMCID: PMC5720314          DOI: 10.1136/bcr-2017-220882

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

Review 1.  Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature.

Authors:  Charudutt Kalamkar; Nishant Radke; Amrita Mukherjee; Snehal Radke
Journal:  BMJ Case Rep       Date:  2016-05-10

2.  Ocular surface squamous neoplasia in xeroderma pigmentosum: clinical spectrum and outcome.

Authors:  Noopur Gupta; Ritika Sachdev; Radhika Tandon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-12       Impact factor: 3.117

3.  Xeroderma pigmentosum. An inherited diseases with sun sensitivity, multiple cutaneous neoplasms, and abnormal DNA repair.

Authors:  J H Robbins; K H Kraemer; M A Lutzner; B W Festoff; H G Coon
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

4.  Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases.

Authors:  K H Kraemer; M M Lee; J Scotto
Journal:  Arch Dermatol       Date:  1987-02

5.  The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin.

Authors:  B Giannotti; L Vanzi; E M Difonzo; N Pimpinelli
Journal:  Clin Exp Dermatol       Date:  2003-11       Impact factor: 3.470

6.  Combined excision, cryotherapy, and intraoperative mitomycin C (EXCRIM) for localized intraepithelial and squamous cell carcinoma of the conjunctiva.

Authors:  Ahmet M Sarici; Sema Arvas; Halit Pazarli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-08-16       Impact factor: 3.117

Review 7.  Xeroderma pigmentosum.

Authors:  Alan R Lehmann; David McGibbon; Miria Stefanini
Journal:  Orphanet J Rare Dis       Date:  2011-11-01       Impact factor: 4.123

8.  Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial.

Authors:  Erick Marcet Santiago de Macedo; Rachel Camargo Carneiro; Patricia Picciarelli de Lima; Breno Gonçalves Silva; Suzana Matayoshi
Journal:  BMC Ophthalmol       Date:  2015-04-03       Impact factor: 2.209

9.  Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area.

Authors:  Gamze Ozturk Karabulut; Pelin Kaynak; Can Ozturker; Korhan Fazil; Osman Bulut Ocak; Muhittin Taskapılı
Journal:  Indian J Ophthalmol       Date:  2017-01       Impact factor: 1.848

  9 in total
  1 in total

Review 1.  Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence.

Authors:  Maria Vittoria Cicinelli; Alessandro Marchese; Francesco Bandello; Giulio Modorati
Journal:  Ophthalmol Ther       Date:  2018-07-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.